BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17093005)

  • 1. Involvement of breast cancer resistance protein (BCRP/ABCG2) in the biliary excretion and intestinal efflux of troglitazone sulfate, the major metabolite of troglitazone with a cholestatic effect.
    Enokizono J; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Feb; 35(2):209-14. PubMed ID: 17093005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
    Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin.
    Hirano M; Maeda K; Matsushima S; Nozaki Y; Kusuhara H; Sugiyama Y
    Mol Pharmacol; 2005 Sep; 68(3):800-7. PubMed ID: 15955871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular exposure of troglitazone metabolites in rat sandwich-cultured hepatocytes lacking Bcrp and Mrp2: interplay between formation and excretion.
    Yang K; Brouwer KL
    Drug Metab Dispos; 2014 Jul; 42(7):1219-26. PubMed ID: 24799397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of breast cancer resistance protein (ABCG2) in the biliary excretion mechanism of fluoroquinolones.
    Ando T; Kusuhara H; Merino G; Alvarez AI; Schinkel AH; Sugiyama Y
    Drug Metab Dispos; 2007 Oct; 35(10):1873-9. PubMed ID: 17639028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
    Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
    Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the transporters involved in the hepatobiliary transport and intestinal efflux of methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) glucuronide, a pharmacologically active metabolite of S-8921.
    Sakamoto S; Kusuhara H; Horie K; Takahashi K; Baba T; Ishizaki J; Sugiyama Y
    Drug Metab Dispos; 2008 Aug; 36(8):1553-61. PubMed ID: 18474677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bile Salt Homeostasis in Normal and Bsep Gene Knockout Rats with Single and Repeated Doses of Troglitazone.
    Cheng Y; Chen S; Freeden C; Chen W; Zhang Y; Abraham P; Nelson DM; Humphreys WG; Gan J; Lai Y
    J Pharmacol Exp Ther; 2017 Sep; 362(3):385-394. PubMed ID: 28645914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatobiliary disposition of troglitazone and metabolites in rat and human sandwich-cultured hepatocytes: use of Monte Carlo simulations to assess the impact of changes in biliary excretion on troglitazone sulfate accumulation.
    Lee JK; Marion TL; Abe K; Lim C; Pollock GM; Brouwer KL
    J Pharmacol Exp Ther; 2010 Jan; 332(1):26-34. PubMed ID: 19801447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity.
    Nozawa T; Sugiura S; Nakajima M; Goto A; Yokoi T; Nezu J; Tsuji A; Tamai I
    Drug Metab Dispos; 2004 Mar; 32(3):291-4. PubMed ID: 14977862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organic anion transporting polypeptide 2B1 and breast cancer resistance protein interact in the transepithelial transport of steroid sulfates in human placenta.
    Grube M; Reuther S; Meyer Zu Schwabedissen H; Köck K; Draber K; Ritter CA; Fusch C; Jedlitschky G; Kroemer HK
    Drug Metab Dispos; 2007 Jan; 35(1):30-5. PubMed ID: 17020956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice.
    Tian X; Li J; Zamek-Gliszczynski MJ; Bridges AS; Zhang P; Patel NJ; Raub TJ; Pollack GM; Brouwer KL
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3230-4. PubMed ID: 17576841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transporter studies with the 3-O-sulfate conjugate of 17alpha-ethinylestradiol: assessment of human liver drug transporters.
    Han YH; Busler D; Hong Y; Tian Y; Chen C; Rodrigues AD
    Drug Metab Dispos; 2010 Jul; 38(7):1072-82. PubMed ID: 20360302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one).
    Mizuno N; Takahashi T; Kusuhara H; Schuetz JD; Niwa T; Sugiyama Y
    Drug Metab Dispos; 2007 Nov; 35(11):2045-52. PubMed ID: 17682070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ochratoxin A transport by the human breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), and organic anion-transporting polypeptides 1A2, 1B1 and 2B1.
    Qi X; Wagenaar E; Xu W; Huang K; Schinkel AH
    Toxicol Appl Pharmacol; 2017 Aug; 329():18-25. PubMed ID: 28532671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate.
    Funk C; Pantze M; Jehle L; Ponelle C; Scheuermann G; Lazendic M; Gasser R
    Toxicology; 2001 Oct; 167(1):83-98. PubMed ID: 11557132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice.
    Zamek-Gliszczynski MJ; Nezasa K; Tian X; Kalvass JC; Patel NJ; Raub TJ; Brouwer KL
    Mol Pharmacol; 2006 Dec; 70(6):2127-33. PubMed ID: 16959944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats.
    Kostrubsky VE; Vore M; Kindt E; Burliegh J; Rogers K; Peter G; Altrogge D; Sinz MW
    Drug Metab Dispos; 2001 Dec; 29(12):1561-6. PubMed ID: 11717175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.